SCHEMBL19814656

SCHEMBL19814656

Cc1ncnn1-c1ccc(N)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
KDM4E B2RXH2 2/20 0.44
RAD52 P43351 1/20 0.44
ALDH1A1 P00352 6/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 3/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 2/20 0.41
NFKB1 P19838 1/20 0.40
PMP22 Q01453 1/20 0.40
MALT1 Q9UDY8 2/20 0.38
TSHR P16473 1/20 0.38
BRD4 O60885 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29877763 0.81 ALDH1A1 (0.39) MAPTKDM4EALDH1A1SMN1; SMN2GAA
SCHEMBL512812 0.81 ALDH1A1 (0.39) MAPTKDM4EALDH1A1SMN1; SMN2GAA
SCHEMBL21030427 0.79 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2MALT1BRD4LMNA
SCHEMBL511854 0.78 NR4A1 (0.54) MAPTKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL19814266 0.77 KDM4E (0.49) MAPTKDM4EALDH1A1CYP3A4GAA
SCHEMBL12693219 0.76 P2RX7 (0.48) ALDH1A1SMN1; SMN2LMNAP2RX7
SCHEMBL20265554 0.75 MALT1 (0.35) KDM4EPOLBCYP3A4GAAMALT1
SCHEMBL20278384 0.75 MAPT (0.46) MAPTKDM4ERAD52ALDH1A1POLB
SCHEMBL11728537 0.74 MAPT (0.44) MAPTKDM4ERAD52ALDH1A1POLB
SCHEMBL361403 0.73 NR4A1 (0.35) MAPTKDM4EALDH1A1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3558969-B1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-09-18 EP disclosed
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2024-09-03 US disclosed
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. 2022-10-06 US disclosed
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-03-23 US disclosed
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-03-23 US disclosed
US-20210052556-A1 SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS LUPIN LTD (IN) 2021-02-25 US disclosed
EP-3736277-A1 SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS Lupin Limited (IN) 2020-11-11 EP disclosed
EP-3558969-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS Janssen Pharmaceutica NV (BE) 2019-10-30 EP disclosed
US-20190275012-A9 SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS LUPIN LIMITED (IN) 2019-09-12 US disclosed
EP-3490995-A1 SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS Lupin Limited (IN) 2019-06-05 EP disclosed
US-20190160045-A1 SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS LUPIN LTD (IN) 2019-05-30 US disclosed
WO-2018119036-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. (US) 2018-06-28 WO disclosed
WO-2018119036-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN BIOTECH, INC. (US) 2018-06-28 WO disclosed
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN-CILAG (FR) 2018-06-21 US disclosed
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN-CILAG (FR) 2018-06-21 US disclosed
WO-2018020474-A1 SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS LUPIN LIMITED (IN) 2018-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210052556-A1 SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS MALT1, PTP4A1, PTPRO MAPT 2864/4885KDM4E 2530/4885RAD52 4418/4885
US-20220315557-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS MALT1, PPP3R1, SQSTM1 MAPT 2314/4885KDM4E 3526/4885RAD52 3559/4885
US-10954214-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 MAPT 2314/4885KDM4E 3526/4885RAD52 3559/4885
US-20190275012-A9 SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS MALT1, PTP4A1, PTPRO MAPT 2864/4885KDM4E 2530/4885RAD52 4418/4885
US-20190160045-A1 SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS MALT1, PTP4A1, PTPRO MAPT 2864/4885KDM4E 2530/4885RAD52 4418/4885
US-12077521-B2 Pyrazole derivatives as MALT1 inhibitors MALT1, PPP3R1, SQSTM1 MAPT 2314/4885KDM4E 3526/4885RAD52 3559/4885
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS MALT1, PPP3R1, SQSTM1 MAPT 2314/4885KDM4E 3526/4885RAD52 3559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.